Evidence map›Paper›PMID 21932302›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2011

Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

D S Adnan Majid, Adam R Aron, Wesley Thompson, Sarah Sheldon, Samar Hamza, Diederick Stoffers, Dominic Holland, Jody Goldstein, Jody Corey-Bloom, Anders M Dale

Open access · greenAbstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 55 citations in OpenAlex.

  1. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.Movement disorders : official journal of the Movement Disorder Society · 2017
    Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease.Movement disorders : official journal of the Movement Disorder Society · 2016
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Neuroprotective effects of psychotropic drugs in Huntington's disease.International journal of molecular sciences · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

D S Adnan MajidDepartment of Psychology, University of California, San Diego, San Diego, California 92093-0841, USA.
Adam R Aron
Wesley Thompson
Sarah Sheldon
Samar Hamza
Diederick Stoffers
Dominic Holland
Jody Goldstein
Jody Corey-Bloom
Anders M Dale
University of California, San Diego · USNetherlands Institute for Neuroscience · NL

Funding

How inhibitory control prevents thought intrusions and sensory and motor provocationsR01DA026452 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ARON, ADAM ROBERT · 2009 to 2021
$4.0M
Structural & Metabolic Neuroimaging Biomarkers in Early Alzheimer's DiseaseR01AG031224 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DALE, ANDERS M · 2008 to 2012
$1.9M
NIA NIH HHS R01 AG031224NIDA NIH HHS R01 DA026452
6 · The paper itself

Abstract

Future clinical trials of neuroprotection in prodromal Huntington's (known as preHD) will require sensitive in vivo imaging biomarkers to track disease progression over the shortest period. Since basal ganglia atrophy is the most prominent structural characteristic of Huntington's pathology, systematic assessment of longitudinal subcortical atrophy holds great potential for future biomarker development. We studied 36 preHD and 22 age-matched controls using a novel method to quantify regional change from T(1) -weighted structural images acquired 1 year apart. We assessed cross-sectional volume differences and longitudinal volumetric change in 7 subcortical structures-the accumbens, amygdala, caudate, hippocampus, pallidum, putamen, and thalamus. At baseline, accumbens, caudate, pallidum, and putamen volumes were reduced in preHD versus controls (all P < .01). Longitudinally, atrophy was greater in preHD than controls in the caudate, pallidum, and putamen (all P < .01). Each structure showed a large between-group effect size, especially the pallidum where Cohen's d was 1.21. Using pallidal atrophy as a biomarker, we estimate that a hypothetical 1-year neuroprotection study would require only 35 preHD per arm to detect a 50% slowing in atrophy and only 138 preHD per arm to detect a 25% slowing in atrophy. The effect sizes calculated for preHD basal ganglia atrophy over 1 year are some of the largest reported to date. Consequently, this translates to strikingly small sample size estimates that will greatly facilitate any future neuroprotection study. This underscores the utility of this automatic image segmentation and longitudinal nonlinear registration method for upcoming studies of preHD and other neurodegenerative disorders.

Indexed as

AdultAtrophyBasal GangliaBasal Ganglia DiseasesDisease ProgressionFemaleFollow-Up StudiesHippocampusHumansHuntington DiseaseLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedModels, NeurologicalNucleus Accumbens

Identifiers

PMID21932302
PMCPMC5615846
OpenAlexW2162741506

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.